Нечистотии на аминокиселини што се користат за синтетизирање на протеините
Детали за производот
| NO | Производи | Кас бр | Индикатор за квалитет на клучот | |||
| Чистота | Макс. нечистотија | Остаток на вкупно растворувач | Влага | |||
| 1 | FMOC-β-ALA-ALA-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 2 | FMOC-D-ALA-D-ALA-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 3 | FMOC-β-ALA-D-ALA-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 4 | FMOC-ARG (PBF) -ARG (PBF) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 5 | FMOC-β-ALA-ARG (PBF) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 6 | FMOC-D-ARG (PBF) -D-ARG (PBF) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 7 | FMOC-β-ALA-D-ARG (PBF) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 8 | Fmoc-homoarg (pbf) -homoarg (pbf) -ох | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 9 | FMOC-β-Ala-Homoarg (PBF) -о | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 10 | FMOC-ASN (TRT) -ASN (TRT) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 11 | FMOC-β-ALA-ASN (TRT) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 12 | FMOC-ASP (OTBU) -ASP (OTBU) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 13 | FMOC-β-ALA-ASP (OTBU) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 14 | FMOC-CYS (TRT) -CYS (TRT) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 15 | FMOC-β-ALA-CYS (TRT) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 16 | FMOC-CYS (ACM) -CYS (ACM) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 17 | FMOC-β-ALA-CYS (ACM) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 18 | FMOC-GLN (TRT) -GLN (TRT) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 19 | FMOC-β-ALA-GLN (TRT) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 20 | Fmoc-glu (otbu) -glu (otbu) -oh | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 21 | FMOC-β-ALA-GLU (OTBU) -OH.H2O | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 22 | FMOC-β-ALA-GLY-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 23 | Fmoc-his (trt) -his (trt) -oh | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 24 | FMOC-β-ALA-HIS (TRT) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 25 | FMOC-Ile-Ile-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 26 | FMOC-β-Ala-Ile-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 27 | FMOC-Leu-Leu-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 28 | FMOC-β-ALA-Leu-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 29 | FMOC-D-LEU-D-LEU-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 30 | FMOC-β-ALA-D-LEU-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 31 | FMOC-LYS (BOC) -lys (BOC) -о | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 32 | FMOC-β-ALA-LYS (BOC) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 33 | Fmoc-lys (алока) -lys (алока) -о | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 34 | FMOC-β-ала-лис (алока) -о | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 35 | FMOC-MET-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 36 | FMOC-β-ALA-MET-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 37 | FMOC-orn (BOC) -Orn (BOC) -о | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 38 | FMOC-β-ALA-orn (BOC) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 39 | FMOC-PHE-PHE-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 40 | FMOC-β-ALA-PHE-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 41 | FMOC-D-PHE-D-PHE-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 42 | FMOC-β-ALA-D-PHE-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 43 | FMOC-PRO-PRO-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 44 | FMOC-β-ALA-PRO-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 45 | Fmoc-ser (tbu) -ser (tbu) -oh | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 46 | FMOC-β-ALA-ser (TBU) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 47 | FMOC-SER (TRT) -SER (TRT) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 48 | FMOC-β-ALA-ser (TRT) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 49 | Fmoc-thr (tbu) -thr (tbu) -oh | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 50 | FMOC-β-ALA-Thr (TBU) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 51 | FMOC-TRP (BOC) -TRP (BOC) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 52 | FMOC-β-ALA-TRP (BOC) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 53 | FMOC-D-TRP (BOC) -D-TRP (BOC) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 54 | FMOC-β-ALA-D-TRP (BOC) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 55 | FMOC-TYR (TBU) -tyr (TBU) -oh | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 56 | FMOC-β-ALA-TYR (TBU) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 57 | FMOC-D-TYR (ET) -D-TYR (ET) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 58 | FMOC-β-ALA-D-Tyr (ET) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 59 | Fmoc-tyr (me) -tyr (me) -oh | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 60 | FMOC-β-ALA-TYR (ME) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 61 | Fmoc-val-val-oh | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 62 | FMOC-β-ALA-VAL-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 63 | FMOC-D-CIT-D-CIT-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 64 | FMOC-β-ALA-D-CIT-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 65 | FMOC-β-ALA-DAB-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 66 | FMOC- (3- (2-нафтил) -D-ALA) 2-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 67 | FMOC-β-ALA-3- (2-нафтил) -D-Ala-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 68 | FMOC- (3- (3-пиридинил) -D-ALA) 2-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 69 | FMOC-β-ALA-3- (3-пиридинил) -D-ALA-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 70 | FMOC- (4-хлоро-d-phe) 2-ох | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 71 | FMOC-β-ALA-4-CHLORO-D-PHE-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 72 | Fmoc- (d-4aph (tbucbm)) 2-ох | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 73 | FMOC-β-ALA-D-4APH (TBUCBM) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 74 | Fmoc-aph (l-hor) -aph (l-hor) -oh | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 75 | FMOC-β-ала-аф (L-HOR) -OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 76 | FMOC-LYS (IPR, BOC) -lys (IPR, BOC) -о | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 77 | FMOC-β-ALA-LYS (IPR, BOC) -о | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 78 | FMOC-β-ALA-AEEA-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 79 | FMOC-AIB-AIB-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 80 | FMOC-β-ALA-AIB-OH | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 81 | FMOC-ARG-OH | 91000-69-0 | .098,0% | .01,0% | .08,0% | .02,0% |
| 82 | H-ARG (PBF) -о | 200115-86-2 | .098,0% | .01,0% | .08,0% | .02,0% |
| 83 | FMOC-D-ARG-OH | 130752-32-8 | .098,0% | .01,0% | .08,0% | .02,0% |
| 84 | HD-ARG (PBF) -о | 200116-81-0 | .098,0% | .01,0% | .08,0% | .02,0% |
| 85 | Fmoc-homoarg-oh.hcl | 208174-14-5 | .098,0% | .01,0% | .08,0% | .02,0% |
| 86 | H-homoarg (PBF) -ох | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 87 | Fmoc-d-homoarg-ох | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 88 | HD-homoarg (PBF) -ох | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 89 | FMOC-ASN-OH | 71989-16-7 | .098,0% | .01,0% | .08,0% | .02,0% |
| 90 | H-ASN (TRT) -OH | 132388-58-0 | .098,0% | .01,0% | .08,0% | .02,0% |
| 91 | FMOC-ASP-OH | 119062-05-4 | .098,0% | .01,0% | .08,0% | .02,0% |
| 92 | H-Asp (Otbu) -oh | 3057-74-7 | .098,0% | .01,0% | .08,0% | .02,0% |
| 93 | FMOC-CYS-OH | 135248-89-4 | .098,0% | .01,0% | .08,0% | .02,0% |
| 94 | H-cys (TRT) -о | 2799/7/7 | .098,0% | .01,0% | .08,0% | .02,0% |
| 95 | H-Cys (ACM) -OH.HCl | 28798-28-9 | .098,0% | .01,0% | .08,0% | .02,0% |
| 96 | FMOC-GLN-OH | 71989-20-3 | .098,0% | .01,0% | .08,0% | .02,0% |
| 97 | H-gln (trt) -ох | 102747-84-2 | .098,0% | .01,0% | .08,0% | .02,0% |
| 98 | FMOC-GLU-OH | 121343-82-6 | .098,0% | .01,0% | .08,0% | .02,0% |
| 99 | H-glu (otbu) -oh.h2o | 2419-56-9 | .098,0% | .01,0% | .08,0% | .02,0% |
| 100 | FMOC-HIS-OH | 116611-64-4 | .098,0% | .01,0% | .08,0% | .02,0% |
| 101 | H-HIS (TRT) -OH | 35146-32-8 | .098,0% | .01,0% | .08,0% | .02,0% |
| 102 | Боц-Хис-ох | 17791-52-5 | .098,0% | .01,0% | .08,0% | .02,0% |
| 103 | FMOC-LYS-OH | 105047-45-8 | .098,0% | .01,0% | .08,0% | .02,0% |
| 104 | H-Lys (BOC) -о | 2418-95-3 | .098,0% | .01,0% | .08,0% | .02,0% |
| 105 | H-lys (алока) -ох | 6298/3/9 | .098,0% | .01,0% | .08,0% | .02,0% |
| 106 | FMOC-ORN-OH.HCL | 201046-57-3 | .098,0% | .01,0% | .08,0% | .02,0% |
| 107 | H-orn (BOC) -о | 13650-49-2 | .098,0% | .01,0% | .08,0% | .02,0% |
| 108 | Fmoc-ser-oh | 73724-45-5 | .098,0% | .01,0% | .08,0% | .02,0% |
| 109 | H-Ser (TBU) -о | 18822-58-7 | .098,0% | .01,0% | .08,0% | .02,0% |
| 110 | H-Ser (TRT) -о | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 111 | Fmoc-thr-oh.h2o | 73731-37-0 | .098,0% | .01,0% | .08,0% | .02,0% |
| 112 | H-thr (tbu) -oh | 4378-13-6 | .098,0% | .01,0% | .08,0% | .02,0% |
| 113 | FMOC-TRP-OH | 35737-15-6 | .098,0% | .01,0% | .08,0% | .02,0% |
| 114 | H-TRP (BOC) -о | 146645-63-8 | .098,0% | .01,0% | .08,0% | .02,0% |
| 115 | FMOC-D-TRP-OH | 86123-11-7 | .098,0% | .01,0% | .08,0% | .02,0% |
| 116 | HD-TRP (BOC) -о | 201290-11-1 | .098,0% | .01,0% | .08,0% | .02,0% |
| 117 | FMOC-TYR-OH | 92954-90-0 | .098,0% | .01,0% | .08,0% | .02,0% |
| 118 | H-TYR (TBU) -OH | 18822-59-8 | .098,0% | .01,0% | .08,0% | .02,0% |
| 119 | FMOC-D-TYR-OH | 112883-29-1 | .098,0% | .01,0% | .08,0% | .02,0% |
| 120 | HD-Tyr (ET) -о | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 121 | H-tyr (me) -oh.hcl | 67423-44-3 | .098,0% | .01,0% | .08,0% | .02,0% |
| 122 | FMOC-D-4APH (CBM) -о | 324017-22-3 | .098,0% | .01,0% | .08,0% | .02,0% |
| 123 | HD-4aph (tbucbm) -ох | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 124 | FMOC-LYS (IPR) -ОХ | NA | .098,0% | .01,0% | .08,0% | .02,0% |
| 125 | H-Lys (IPR, BOC) -о | NA | .098,0% | .01,0% | .08,0% | .02,0% |
За
Компензација
Gentolex обезбедува производи со одличен квалитет, доколку клиентот е зголемен од кој било квалитет на производот во рамките на потребната временска рамка со доволни докази, ние ќе обезбедиме неопходна анализа и проценка за да ги активираме процедурите за компензации.
Производство
Капацитетите на фармацевтските производи достигнаа тони одделение, капацитетите на хемиските производи достигнуваат 100 тони+ одделение, можностите се добро опремени за да им служат на клиентите ширум светот.
Истражување и развој
Секоја година, постои план поставен од тимот на R&D за развој на различни нови производи, кога поставени цели, секој член во тимот ќе мора да продолжи со одговорност на КПИ и со политика за стимулирање.
